Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment

This study is currently recruiting participants.
Information provided by National Institute of Mental Health (NIMH)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Depression
2		More general conditions related to this trial
			Behavioral Symptoms
3		Interventions listed in this trial
			Escitalopram
			Placebo
			IL-2
4		Additional drug interventions recognized in this trial
			Citalopram
			Dexetimide
			Interleukin-2
5		More general drug interventions related to this trial
			Analgesics
			Analgesics, Non-Narcotic
			Anti-Dyskinesia Agents
			Antidepressive Agents
			Antidepressive Agents, Second-Generation
			Antineoplastic Agents
			Antiparkinson Agents
			Autonomic Agents
			Central Nervous System Agents
			Cholinergic Agents
			Cholinergic Antagonists
			Molecular Mechanisms of Pharmacological Action
			Muscarinic Antagonists
			Neurotransmitter Agents
			Neurotransmitter Uptake Inhibitors
			Parasympatholytics
			Peripheral Nervous System Agents
			Pharmacologic Actions
			Physiological Effects of Drugs
			Psychotropic Drugs
			Sensory System Agents
			Serotonin Agents
			Serotonin Uptake Inhibitors
			Therapeutic Uses
6		Sponsors listed in this trial
			National Institute of Mental Health (NIMH)